Hormonal
Exogenous administration of spermidine or spermine improves glucose homeostasis, insulin sensitivity, and reduces adiposity in diet-induced obesity mouse models.
Current research indicates that spermidine and spermine supplementation may improve metabolic health in obese individuals, particularly by enhancing insulin sensitivity and reducing fat accumulation. However, most evidence comes from animal models. While human trials show increased blood levels with supplementation, direct metabolic benefits in humans are not yet fully established. Consult a healthcare provider before starting supplementation, especially if you have existing metabolic conditions.
Furthermore, the administration of either spermidine or spermine has been shown to be effective for improving glucose homeostasis and insulin sensitivity and reducing adiposity and hepatic fat accumulation in diet-induced obesity mouse models.
Why this rating
Evidence is derived from multiple animal models (mice/rats) and in vitro studies, but lacks direct human clinical trial data confirming efficacy in humans.
Source
Dietary and Gut Microbiota Polyamines in Obesity- and Age-Related Diseases
Bruno Ramos‐Molina et al. · Frontiers in Nutrition · 2019
DOI 10.3389/fnut.2019.00024
More from this paper
- Dietary polyamines (spermidine, spermine, putrescine) are absorbed from the gut, and prolonged oral supplementation increases blood levels of these polyamines in both animal and human subjects.Good
- Agmatine, a polyamine-related compound produced by gut bacteria and plants, reduces body weight gain, fat depots, and atherosclerotic lesions in high-fat diet-fed animal models.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →